These payloads block a cell signal that drives some melanomas. An antibody carries the inhibitor into cells bearing a melanoma-associated surface protein.
DYP688 targets the surface protein PMEL and delivers the Gq/11 inhibitor SDZ475. A published phase 1 study in metastatic uveal melanoma and other GNAQ/GNA11-mutant melanomas reported human safety and preliminary activity. This is direct pathway inhibition rather than a conventional tubulin or DNA-damaging payload. The study was an early dose-escalation trial, so it does not establish a comparative survival benefit or approval.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/